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Introduction {#sec001}
============

Zika virus (ZIKV) is a mosquito-transmitted flavivirus that was first isolated in 1947 in the Zika forest of Uganda from a sentinel rhesus macaque \[[@pntd.0006524.ref001]\]. Since its discovery, human ZIKV cases have been reported across Africa and Asia, but until 2007 the virus received little attention from researchers as it was thought to cause only mild disease. Following epidemics in Micronesia in 2007, French Polynesia in 2013, and Brazil in 2015 \[[@pntd.0006524.ref002]\], ZIKV has now been confirmed as a cause of the neurological disease Guillain-Barre syndrome and congenital disorders, including microcephaly in infants \[[@pntd.0006524.ref003]\]. Despite a dramatic decline in Brazilian cases since 2016, ZIKV remains a significant global human health threat \[[@pntd.0006524.ref004]\], as other countries including Argentina, Bolivia, Peru, and Ecuador reported an increase in cases in 2017 \[[@pntd.0006524.ref005]\].

Reducing mosquito vector populations is an effective way to mitigate mosquito-borne disease transmission \[[@pntd.0006524.ref006]\]. Therefore, identifying ZIKV vector species is crucial for accurate risk assessments for mosquito transmission and to target vector control measures to mitigate ZIKV disease. Several *Aedes* species have been identified as competent vectors in laboratory studies, including the primary vector *Aedes* (*Ae*.) *aegypti* \[[@pntd.0006524.ref007]--[@pntd.0006524.ref021]\], *Ae*. *albopictus* \[[@pntd.0006524.ref007],[@pntd.0006524.ref008],[@pntd.0006524.ref010],[@pntd.0006524.ref011],[@pntd.0006524.ref015],[@pntd.0006524.ref017],[@pntd.0006524.ref019],[@pntd.0006524.ref020],[@pntd.0006524.ref022],[@pntd.0006524.ref023]\], *Ae*. *notoscriptus* \[[@pntd.0006524.ref010]\], *Ae*. *camptorhynchus* \[[@pntd.0006524.ref010]\], *Ae*. *luteocephalus* \[[@pntd.0006524.ref024]\], *Ae*. *vexans* \[[@pntd.0006524.ref025]\], and *Ae*. *vittatus* \[[@pntd.0006524.ref024]\]. *Culex* species generally do not become infected with ZIKV and are incapable of transmitting \[[@pntd.0006524.ref007],[@pntd.0006524.ref009],[@pntd.0006524.ref010],[@pntd.0006524.ref012],[@pntd.0006524.ref014],[@pntd.0006524.ref017],[@pntd.0006524.ref023],[@pntd.0006524.ref026]--[@pntd.0006524.ref029]\]. Exceptions include a study from Guadalajara, Mexico, where infectious ZIKV was detected in pooled mosquito tissue samples from field-collected *Cx*. *tarsalis*, *Cx*. *coronator*, and *Cx*. *quinquefasciatus* \[[@pntd.0006524.ref030]\]. ZIKV RNA has also been detected in pooled field samples of *Cx*. *quinquefasciatus* from China \[[@pntd.0006524.ref031]\]. Evidence for ZIKV transmission by *Culex* species is limited to *Cx*. *quinquefasciatus* and includes ZIKV RNA detected in saliva on Flinders Technology Associates (FTA) cards provided to a cohort of laboratory-infected mosquitoes from Brazil \[[@pntd.0006524.ref032]\] and transmission to 1-day-old mice from mosquitoes from China, although inconsistently with other murine studies \[[@pntd.0006524.ref033]--[@pntd.0006524.ref035]\], no murine fatality was noted \[[@pntd.0006524.ref036]\].

Previous studies demonstrate that ZIKV vector competence is more complex than simple mosquito species-level designations, and thus region-specific mosquito genotypes and multiple ZIKV strains must be evaluated to assess region-specific vector competence. For example, *Ae*. *aegypt*i from the Dominican Republic transmit ZIKV isolated from Cambodia in 2010 (FSS 13025) and Mexico in 2015 (MEX1-7) more effectively than *Ae*. *aegypti* from Salvador, Brazil \[[@pntd.0006524.ref021]\]. Furthermore, ZIKV from Brazil in 2015 (BeH815744) has higher infectivity than a French Polynesian strain from 2013 (H/PF13) in *Ae*. *aegypti* from Singapore \[[@pntd.0006524.ref008]\]. The source of virus also matters; fresh ZIKV was more infectious in comparative studies than freeze-thawed virus \[[@pntd.0006524.ref012]\].

California (CA) vector control districts have been combating stable *Ae*. *aegypti* populations in the state since 2013 \[[@pntd.0006524.ref037]\], including in many counties in Southern CA. In addition, between 2015 and March 2018, 640 travel-associated ZIKV infections were reported in CA \[[@pntd.0006524.ref038]\], 137 (21% of cases in state) of which were in Los Angeles County where the *Ae*. *aegypti* used for vector competence experiments here were collected. Due to the presence of *Ae*. *aegypti* and numerous travel-associated ZIKV infections, there is a risk of the establishment of local mosquito-borne ZIKV transmission. Additionally, genetic variation between Central Valley and Southern CA *Ae*. *aegypti* populations has been observed \[[@pntd.0006524.ref039]\], even between populations in neighboring cities, such as Fresno and Clovis \[[@pntd.0006524.ref040]\]. These findings indicate that gene flow is limited between *Ae*. *aegypti* populations and leave open the possibility that important traits, such as vector competence, may also vary among *Ae*. *aegypti* throughout the state. To better assess local ZIKV transmission risk, we evaluated the laboratory vector competence of *Ae*. *aegypti* from Los Angeles, CA, for ZIKV isolates from Puerto Rico (2015), Brazil (2015), and Malaysia (1966). We also evaluated the laboratory vector competence of two highly abundant *Culex* species, *Cx*. *quinquefasciatus* from Orange County, CA, and *Cx*. *tarsalis* from Kern County, CA, with a Puerto Rico (2015) ZIKV strain.

Materials and methods {#sec002}
=====================

Sources of ZIKV strains, mosquitoes, and mice {#sec003}
---------------------------------------------

Three Asian-lineage strains of ZIKV were used in our experiments. A 2015 Puerto Rican strain was isolated from human serum in 2015 (PR15, PRVABC59), passaged 4 times in Vero cells, and sequenced. The coding sequence for the complete genome of the passaged we used was identical to GenBank accession number KX601168. An Asian-lineage Malaysian ZIKV strain isolated from *Ae*. *aegypti* mosquitoes in 1966 (MA66, P6-740 \[[@pntd.0006524.ref041]\]) that had been passaged in suckling mouse brains 6 times and once in Vero cells before it was received from the Centers for Disease Control was passaged once more in Vero cells. The complete coding genome sequence of our passage of MA66 was 100% identical to GenBank accession number KX601167.1. A Brazilian strain isolated from human serum in 2015 (BR15, SPH2015) was passaged 3 times in Vero cells and sequenced. The complete genome coding sequence of BR15 was identical to GenBank accession number KU321639. Strains MA66 and PR15 were obtained from Dr. Aaron Brault at the U.S. Centers for Disease Control and Prevention in Fort Collins, Colorado. Dr. Mike Busch at Blood Systems Research Institute, San Francisco, CA, provided the BR15 strain. All ZIKV strains and their source Vero cells were confirmed mycoplasma negative by PCR according to the manufacturer's instructions (Agilent Mycoplasma Plus PCR Primer Kit, Santa Rosa, CA.)

The *Ae*. *aegypti* mosquitoes used in this study were field-collected as larvae in Los Angeles, CA, in 2016 and morphologically identified. The F6 generation was used for this study. Adult *Cx*. *quinquefasciatus* mosquitoes were field-collected as adults in Orange County, California in 2016 and morphologically identified. The F5 generation was used for this study. The *Cx*. *tarsalis* mosquitoes were field-collected in the Kern National Wildlife Refuge, Kern County, CA in 2002, morphologically identified, and have been maintained continuously in colony since.

Female interferon-deficient (IFN-α/βR−/−; C57BL/6) mice aged 4--8 weeks (B6.129S2-Ifnar1tm1Agt/Mmjax, The Jackson Laboratory, Sacramento, CA) were used for all experiments. Differences in ZIKV viremia levels and kinetics in male versus female mice have not been observed \[[@pntd.0006524.ref033]\].

ZIKV vector competence experiments {#sec004}
----------------------------------

Mice were inoculated with 5 log~10~ Vero plaque forming units (PFU) of ZIKV via subcutaneous injection. ZIKV-infected mice were presented to mosquitoes 2 days post-inoculation, at peak viremia \[[@pntd.0006524.ref033]\]. Mice were anesthetized prior to mosquito exposure with a ketamine (VETone Zetamine CIII, 75 mg/kg), xylazine (AnaSed, 10 mg/kg), and acepromazine (AceproJect, 1 mg/kg) solution administered intraperitoneally. The ZIKV viremia in each mouse was determined by Vero cell plaque assay from 30 μL of whole blood collected immediately prior to the mosquito feed. Viremic mice were presented for two cohorts of adult female mosquitoes 30--60 minutes on one of three arrangements depending on species: (1) 25 *Cx*. *tarsalis* in pint cartons ([amazon.com](http://amazon.com)), (2) 50 *Ae*. *aegypti* in pint cartons, or (3) \>100 *Cx*. *quinquefasciatus* in a 1 ft^3^ mesh cage (BugDorm, MegaView Science, Taiwan). Engorged females were sorted from non-fed individuals by vacuum aspiration. Mosquito ages at the time of blood-feeding were 4--14 days post eclosion (dpe) for *Cx*. *tarsalis*, 14--21 dpe for *Cx*. *quinquefasciatus*, and 4--12 dpe for *Ae*. *aegypti*. *Cx*. *tarsalis* and *Ae*. *aegypti* were held at 26°C, 80% relative humidity, and 12:12 h light:dark cycle. *Cx*. *quinquefasciatus* were maintained at room temperature (22°C and 33% relative humidity) to ensure survival. All mosquitoes had constant access to 10% sucrose before and after blood-feeding, except during a 24-hour starvation period prior to presentation of the viremic mice. At days 14 and 21 post bloodfeed, mosquitoes were cold-anesthetized at -20°C for 5 minutes and then legs and wings were removed with forceps while immobilized on ice. Saliva was collected by inserting the proboscis into a capillary tube containing fetal bovine serum (FBS, GenClone) for 20 minutes. Individual bodies, legs+wings, and the saliva sample from each mosquito were stored separately in 2 mL tubes containing a 5 mm glass bead and 250 μL Dulbecco's modified eagle medium (DMEM, Gibco) supplemented with 50μg/mL of penicillin/streptomycin and 20% FBS. All samples were stored at -80°C until further processing.

ZIKV RNA extraction {#sec005}
-------------------

Mosquito tissues and glass capillary tubes containing saliva samples were homogenized in DMEM by shaking for 2 minutes at 30 shakes/second using a Tissuelyser (Qiagen, Hilden, Germany). Viral RNA was extracted using the MaxMax Viral RNA Extraction Kit (ThermoFisher, Waltham, MA). A total of 50 μL of homogenate for mosquito tissue and 100 μL of saliva samples were extracted. All RNA extracts were eluted in 50 μL of elution buffer (Buffer EB, Qiagen) and stored at -80°C until further testing.

ZIKV RT-qPCR {#sec006}
------------

ZIKV RNA titers were determined for each body, legs+wings, and saliva sample using the Taqman Fast Virus One-Step Master Mix (ThermoFisher) reverse transcription RT-qPCR kit with a previously described ZIKV-specific assay (primers: ZIKV 1086, ZIKV 1162c, and ZIKV 1107-FAM; \[[@pntd.0006524.ref042]\]). At least two technical replicates were performed for all samples. Samples with a mean cycle threshold (Ct) value of 38 or below were considered positive for ZIKV RNA. This limit of detection was determined from prior testing of serially diluted samples of known ZIKV RNA concentrations with the same extraction and RT-qPCR reagents and protocols and equipment \[[@pntd.0006524.ref043]\].

Infectivity of mosquito saliva {#sec007}
------------------------------

To estimate infectious ZIKV in expectorated *Ae*. *aegypti* saliva, viral titrations were performed on a random sample of RT-qPCR-positive saliva samples at the second or third thaw in Vero cell culture by plaque assay. In brief, cell monolayers were inoculated with 110 μL of undilute saliva from individual mosquitoes mixed with DMEM containing 2% (vol/vol) FBS, and 100 U/mL penicillin/streptomycin. After a one hour incubation period to allow for viral infection of cells, 0.8% agarose/DMEM was added to cover the cells. The plates were incubated at 37°C in 5% CO~2~ for 8 days. The cells were then fixed with 4% formaldehyde and stained with 0.05% crystal violet. Plaques were visualized as holes in the Vero cell monolayer and counted to determine PFU values. The limit of detection of the assay was 2.3 PFU where 110 μL of the total saliva sample (250 μL) was inoculated directly onto the cells. Since the volume of saliva was limited, each sample was tested in just 1 replicate.

Infection definitions, cohort grouping, and statistical analyses {#sec008}
----------------------------------------------------------------

In this study, we calculated infection rates as the number of RT-qPCR positive individual bodies divided by the number of individuals that ingested blood and were tested, dissemination rates as the number of RT-qPCR positive pooled leg & wing sets from each individual divided by the number of individuals that ingested blood and were tested, and transmission rates as the number of RT-qPCR positive saliva samples divided by the total number of individuals that ingested blood and were tested. For *Ae*. *aegypti* and *Cx*. *tarsalis*, multiple cohorts of the same species fed on different mice infected with the same ZIKV strain with slight (≤1 log~10~) variations in viremias. Preliminary analysis across same-species cohorts that fed on different mice infected with the same ZIKV strain revealed no significant differences (Fisher's exact test, *P*\>0.05) in infection, dissemination and transmission rates. We therefore combined the data presented for each ZIKV strain for *Ae*. *aegypti* and *Cx*. *tarsalis*, while also reporting the magnitudes of viremia in all mice ([Table 1](#pntd.0006524.t001){ref-type="table"}). Comparisons of ZIKV RNA levels and PFU in saliva samples between ZIKV strains was performed using a one-way ANOVA with Tukey's correction for pairwise comparisons (reported as *P*~adj~) and ZIKV RNA detection rates were compared using two-tailed Fisher's exact tests (scipy.stats). Data were plotted using matplotlib (Python).

10.1371/journal.pntd.0006524.t001

###### ZIKV infection, dissemination, and transmission rates in California *Aedes* and *Culex* mosquitoes 14 and 21 days post ingestion of blood from viremic mice.

![](pntd.0006524.t001){#pntd.0006524.t001g}

  Mosquito Species               Source in California   Generation   ZIKV strain   Blood titer log~10~ PFU/mL   Infected (%)                                          Disseminated (%)   Transmitted (%)                                                                                                             
  ------------------------------ ---------------------- ------------ ------------- ---------------------------- ----------------------------------------------------- ------------------ ---------------------------------------------------- ---------------- ----------------------------------------------------- ----------------
  ***Cx*. *tarsalis***           **Kern County**        **Colony**   **PR15**      **5.7, 6.4, 5.4**            **2/46 (4)**                                          **6/20 (30)**      **2/46 (4)**                                         **1/20 (5)**     **0/46 (0)**                                          **0/20 (0)**
  ***Cx*. *quinquefasciatus***   **Los Angeles**        **F5**       **PR15**      **4.6**                      **0/42 (0)**                                          **0/37 (0)**       **0/42 (0)**                                         **0/37 (0)**     **0/42 (0)**                                          **0/37 (0)**
  ***Ae*. *aegypti***            **Los Angeles**        **F6**       **MA66**      **4.3, 4.8**                 **73/85 (86)**                                        **22/23 (96)**     **69/85 (79)**                                       **21/23 (91)**   **45/85 (53)**                                        **20/23 (87)**
  ***Ae*. *aegypti***            **Los Angeles**        **F6**       **PR15**      **5.7, 6.4, 5.4**            **39/46 (85)**                                        **22/23 (96)**     **36/46 (78)**                                       **18/23 (78)**   **30/46 (65)**                                        **17/23 (74)**
  ***Ae*. *aegypti***            **Los Angeles**        **F6**       **BR15**      **4.7**                      **18/20[\*](#t001fn002){ref-type="table-fn"} (90)**   **n.c.**           **18/20[\*](#t001fn002){ref-type="table-fn"}(90)**   **n.c.**         **15/20 [\*](#t001fn002){ref-type="table-fn"}(75)**   **n.c.**

Infection, dissemination, and transmission rates in mosquitoes that ingested ZIKV from viremic mice, determined by ZIKV RNA detection in bodies, legs+wings, and saliva, respectively. Denominators in rates represent all mosquitoes in cohorts. Multiple values in the mouse blood titer column show viremias for individual mice just before mosquitoes were presented to feed; cohorts of mosquitoes that fed on different mice within this range of viremias were combined since preliminary analysis of each cohort showed no differences in infection, dissemination and transmission rates (data not shown). n.c. indicates samples were not collected at that time point.

\**Ae*. *aegypti* that ingested BR15 were harvested 15 dpf.

Ethics statement {#sec009}
----------------

All procedures involving mice were performed in accordance with IACUC protocol \#19404 that was reviewed and approved by the UC Davis IACUC on June 29, 2017. The UC Davis IACUC adheres to the Office of Laboratory Animal Welfare Health Research Extension Act of 1985 (Public Law 99--158) as well as the United State Department of Agriculture's Animal Welfare Act. UC Davis is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC) and has an Animal Welfare Assurance (number A3433-01) on file with the Office of Laboratory Animal Welfare (OLAW).

Results {#sec010}
=======

*Cx*. *tarsalis* and *Cx*. *quinquefasciatus* from California were incapable of transmitting Puerto Rican ZIKV in laboratory vector competence experiments {#sec011}
----------------------------------------------------------------------------------------------------------------------------------------------------------

*Cx*. *tarsalis* and *Cx*. *quinquefasciatus* mosquitoes were tested 14 or 21 days after ingesting blood from ZIKV-infected interferon receptor deficient mice. Two *Cx*. *tarsalis* bodies out of the 46 individuals tested (4%) had low levels of ZIKV RNA at 14 dpf (Ct \< 38; 48 ZIKV genomes/body). Both infected individuals also had detectable ZIKV in their legs and wings, indicating disseminated infections. Neither of the ZIKV-infected *Cx*. *tarsalis* contained detectable ZIKV RNA in their saliva samples ([Table 1](#pntd.0006524.t001){ref-type="table"}). The *Cx*. *tarsalis* infection rate significantly increased from 4% to 30% (2/46 to 6/20, *P*\<0.01 Fisher exact test) from 14 to 21 dpf. Among the 6 infected *Cx*. *tarsalis* at 21 dpf, ZIKV RNA was detected in 1 leg and wing sample but, consistent with a lack of transmission 14 dpf, no ZIKV RNA was detected in the saliva ([Table 1](#pntd.0006524.t001){ref-type="table"}). We did not detect ZIKV RNA in any *Cx*. *quinquefasciatus* mosquito tissues 14 (N = 42) or 21 dpf (N = 37; [Table 1](#pntd.0006524.t001){ref-type="table"}).

*Ae*. *aegypti* from Los Angeles, CA, were highly competent laboratory ZIKV vectors {#sec012}
-----------------------------------------------------------------------------------

At 14 dpf, ZIKV infection, dissemination, and transmission rates measured by the presence of ZIKV RNA in *Ae*. *aegypti* that ingested MA66 were 86%, 79%, and 53%, respectively ([Table 1](#pntd.0006524.t001){ref-type="table"}). For *Ae*. *aegypti* that ingested ZIKV PR15, the infection, dissemination, and transmission rates on 14 dpf were 85%, 78%, and 65%, respectively ([Table 1](#pntd.0006524.t001){ref-type="table"}). ZIKV BR15-exposed individuals harvested 15 dpf had infection, dissemination, and transmission rates of 90%, 90%, and 75%, respectively ([Table 1](#pntd.0006524.t001){ref-type="table"}). ZIKV RNA infection, dissemination, and transmission rates in *Ae*. *aegypti* that ingested MA66 or PR15 at 21 dpf were equal or higher than 14 dpf rates. The transmission rate between 14 and 21 dpf increased significantly in *Ae*. *aegypti* infected with MA66 (53% vs. 87%, *P*\<0.01, Fisher's exact), but not PR15 (65% vs. 74%, *P* = 0.59, Fisher's exact; [Table 1](#pntd.0006524.t001){ref-type="table"}). Transmission rates were not significantly different across viruses (*P* = 0.13, Fisher's exact).

The mean ZIKV RNA level (8.9 log~10~) in MA66-infected bodies was significantly higher than the mean for BR15 (8.2 log~10~, ANOVA, degrees of freedom (df) = 2, F-statistic (F) = 16.3, *P*~adj~\<0.01) and PR15-infected individuals (8.4 log~10~, ANOVA, df = 2, F = 16.3, *P*~adj~\<0.01; [Fig 1](#pntd.0006524.g001){ref-type="fig"}). The mean ZIKV RNA level in MA66-infected leg+wing tissue (7.5 log~10~) was also significantly higher than PR15-infected leg+wing samples (7.0 log~10~, ANOVA, df = 2, F = 8.4, *P*~adj~\<0.01). Higher ZIKV RNA levels in MA66-infected *Ae*. *aegypti* likely do not reflect the dose ingested, where flavivirus infections of mosquitoes typically show a strong dose response, since viremias in both ZIKV MA66-infected mice were lower than those for PR15. ZIKV RNA levels in saliva were not significantly different among strains (ANOVA, df = 2, F = 0.96, *P* = 0.39).

![Infecting (bodies), disseminating (legs+wings) and transmitted (saliva) ZIKV RNA levels 14 or 15 days after *Ae*. *aegypti* orally ingested one of three Asian lineage ZIKV strains.\
Each dot represents the mean log~10~ ZIKV genome copies per tissue or saliva sample from an individual *Ae*. *aegypti*. *Ae*. *aegypti* from Los Angeles, California, USA, were fed on viremic mice infected with ZIKV from Malaysia 1966 (MA66), Puerto Rico 2015 (PR15) or Brazil 2015 (BR15). Mosquitoes exposed to BR15 were assayed 15 dpf, MA66 and PR15 cohorts were assayed 14 dpf. Each dot represents the mean of two or more RT-qPCR technical replicates. The dashed lines represent the limits of detection (LOD). Dots below dashed line represent tested samples with an undetectable Ct or a Ct value of \>38. The LOD for saliva was lower than for tissues because RNA was extracted from a higher proportion of the saliva sample volume. Asterisks show significant differences in means across groups of the same tissue type, *P*\<0.01, ANOVA, Tukey post-hoc test. No asterisk indicates no significant difference across groups.](pntd.0006524.g001){#pntd.0006524.g001}

A bimodal distribution of ZIKV RNA levels was observed across cohorts of ZIKV PR15- or MA66-infected bodies, with high (\>6 log~10~ genomes/body) and low (\<6 log~10~ genomes/body) clusters of individuals ([Fig 1](#pntd.0006524.g001){ref-type="fig"}). MA66-infected *Ae*. *aegypti* that were highly infected (\>6 log~10~ genomes/body) had higher transmission rates (81%, N = 54) compared to low titer (\<6 log~10~ genomes/body) individuals (5%, N = 19; *P*\<0.0001, Fisher's exact). We also examined the relationship between infection, dissemination and transmission at an individual mosquito level for *Ae*. *aegypti* ([Fig 2](#pntd.0006524.g002){ref-type="fig"}). Most *Ae*. *aegypti* that became infected developed disseminated infections. Individuals with higher (red/pink in figure) ZIKV RNA levels in legs+wings were more likely to transmit ZIKV RNA than mosquitoes with low (blue in figure) RNA levels in legs+wings. None of the PR15-infected *Ae*. *aegypti* with \<6 log~10~ genomes/body transmitted ZIKV RNA (N = 4).

![Individual mosquito ZIKV RNA levels in body, legs+wings, and saliva of *Aedes aegypti* from Los Angeles, CA, USA.\
*Ae*. *aegypti* from Los Angeles ingested blood from viremic ZIKV-infected interferon receptor deficient mice that had been inoculated with different ZIKV strains. Each colored box represents an individual mosquito sample showing the magnitude of ZIKV RNA detected in each body (B), legs+wings (LW), and saliva (S). The red to blue color scale shows high (red) to low (blue) ZIKV RNA levels. Samples with no detectable ZIKV RNA are colored white. ZIKV BR15-infected mosquitoes were not tested 21 dpf.](pntd.0006524.g002){#pntd.0006524.g002}

To confirm infectivity and measure the transmitted ZIKV dose, plaque assays were performed on *Ae*. *aegypti* saliva collected 14 or 15 dpf to enumerate infectious ZIKV in Vero cell plaque forming units (PFU). Out of 45 RTq-PCR positive saliva samples that were tested by plaque assay, 32 (71%) yielded at least 1 detectable plaque. The expectorated PFU varied by viral strain: the MA66-infected individuals transmitted 13±4 PFU (mean±SE, N = 13) compared to 29±6 for PR15 (N = 13) and 35±8 for BR15 (N = 6; ANOVA, df = 2, F = 3.8, *P* = 0.035; [Fig 3](#pntd.0006524.g003){ref-type="fig"}).

![Infectious ZIKV levels in expectorated *Ae*. *aegypti* saliva.\
Saliva from *Ae*. *aegypti* mosquitoes from Los Angeles, CA, USA, infected with either MA66, PR15, or BR15 ZIKV was collected in capillary tubes 14 (MA66 and PR15) or 15 (BR15) dpf. Vero cell plaque assays were performed on RT-qPCR positive saliva expectorants to quantify infectious viruses. The limit of detection (LOD) of the assay was 2.3 PFU and is shown as a dashed line. Dots below the dashed line represent saliva samples with no detectable plaques.](pntd.0006524.g003){#pntd.0006524.g003}

Discussion {#sec013}
==========

Understanding the mosquito species that vector ZIKV is important for estimating regional outbreak potential and for informing local mosquito control strategies, especially since *Aedes* and *Culex* species differ in life history traits and host-seeking behaviors that could impact control efforts. For example, oviposition traps bias towards *Ae*. *aegypti* that lay in artificial containers \[[@pntd.0006524.ref044]\] while *Culex* typically prefer natural pools \[[@pntd.0006524.ref045]\]. For *Cx*. *tarsalis*, we detected an overall ZIKV infection rate of 12% (8/66) in mosquitoes tested 14 and 21 dpf. Disseminated infections in *Cx*. *tarsalis* were detected at \<5% on both 14 and 21 dpf, with high Ct values indicating low ZIKV RNA levels. We postulate that the disseminated infections detected in *Cx*. *tarsalis* may reflect false positives given that mosquitoes with true disseminated infections typically achieve very high viral RNA titers due to prolonged infection of multiple tissues. The absence of detectable ZIKV RNA in saliva at 14 or 21 dpf is evidence that *Cx*. *tarsalis* from CA is not capable of transmitting ZIKV in laboratory experiments. Furthermore, *Cx*. *tarsalis* feeds less often on human hosts compared to the highly anthropophilic *Ae*. *aegypti* \[[@pntd.0006524.ref045]--[@pntd.0006524.ref047]\], making human-mosquito-human ZIKV transmission by *Cx*. *tarsalis* unlikely. We also found no evidence for ZIKV infection of *Cx*. *quinquefasciatus* from California, with no ZIKV RNA detected in bodies, legs/wings or saliva from nearly 80 individuals. This is the first data showing ZIKV vector competence for California mosquitoes, and it supports results from many other studies which demonstrate that *Cx*. *quinquefasciatus* is not a competent laboratory vector of ZIKV. By contrast, *Ae*. *aegypti* mosquitoes exhibited infection rates of 85--90% and transmission rates of 53--80% at 14 dpf. The transmitted dose of infectious ZIKV by Californian *Ae*. *aegypti* is consistent with the range of doses observed in similar studies with Brazilian *Ae*. *aegypti* \[[@pntd.0006524.ref048],[@pntd.0006524.ref049]\].

*Ae*. *aegypti* that ingested ZIKV MA66 in our laboratory vector competence studies developed higher ZIKV RNA levels than PR15- or BR15-infected mosquitoes. This pattern contrasted with the lower transmission rate and lower expectorated PFU of MA66-infected *Ae*. *aegypti* at 14 dpf.

A possible explanation for the lower transmissibility of MA66 at 14 dpf is that it lacks a A188V mutation in the NS1 gene that both PR15 and BR15 possess, which has been linked to higher infectivity (where infectivity can influence transmissibility) in mosquitoes when interferon-deficient mice are used for blood-feeding \[[@pntd.0006524.ref007]\]. ZIKV strains from recent American outbreaks have also been shown to exhibit higher infection and transmission rates than historic Asian-lineage strains \[[@pntd.0006524.ref008]\]. Additional vector competence studies involving region-specific *Ae*. *aegypti* and *Ae*. *albopictus* mosquito populations with sequenced genomes and multiple distinct ZIKV isolates will improve our understanding of the both mosquito and virus genetics involved in ZIKV vector competence, which could inform our ability to accurately estimate regional outbreak potential.

Among ZIKV MA66-infected *Ae*. *aegypti*, we observed that mosquitoes with low RNA copy numbers in bodies were less likely to transmit than those with infections that exceeded 6 log~10~ genomes per body. This pattern is consistent with the presence of a midgut barrier to infection \[[@pntd.0006524.ref050]\]. In that case, the mosquitoes with low body RNA levels represent infections that have not escaped the midgut while mosquitoes with high body RNA levels correspond to individuals with ZIKV that has disseminated to secondary amplification tissues.

This laboratory vector competence study confirmed that *Ae*. *aegypti* from Los Angeles, California, USA, can transmit Asian lineage ZIKV and that *Cx*. *tarsalis* and *Cx*. *quinquefasciatus* are inefficient ZIKV vectors. Given that *Culex* mosquitoes are poor ZIKV vectors and seek primarily non-human hosts, they are unlikely to facilitate a ZIKV outbreak. Thus, vector control efforts targeting ZIKV should remain focused on reducing urban *Aedes* populations.
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